Evidence map›Paper›PMID 18195718›Full record

ArticleMolecular psychiatry2009

Chronic stimulation of corticotropin-releasing factor receptor 1 enhances the anxiogenic response of the cholecystokinin system.

T Sherrin, C Todorovic, T Zeyda, C H Tan, P T H Wong, P W T Hon, Y-Z Zhu, J Spiess

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Molecular psychiatry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Cannabinoid CBNature medicine · 2019
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Suppression of the MEK/ERK signaling pathway reverses depression-like behaviors of CRF2-deficient mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2009
    Article
4 · The record

Corrections and comments

  • Erratum issued
    Hon, P W T [corrected to Wong, P T H]
5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

T SherrinSpecialized Neuroscience Research Program, University of Hawaii, Honolulu, HI 96813, USA.
C Todorovic
T Zeyda
C H Tan
P T H Wong
P W T Hon
Y-Z Zhu
J Spiess
University of Hawaii System · USNational University of Singapore · SGFudan University · CNUniversity of Hawaiʻi at Mānoa · US

Funding

UNIVERSITY OF HAWAII SNRPU54NS039406 · NINDS · UNIVERSITY OF HAWAII AT MANOA · PI NICHOLS, ROBERT · 1999 to 2009
$14.4M
NINDS NIH HHS 5U54NS039406-08
6 · The paper itself

Abstract

Corticotropin-releasing factor (CRF) and cholecystokinin (CCK), two highly colocalized neuropeptides, have been linked to the etiology of stress-related anxiety disorders. Recent evidence points to the possibility that some of the anxiogenic effects of the central CCK system take place through interplay with the CRF system. The aim of the present study was to examine the effects of chronic, mild activation of CRF receptor 1 (CRF(1)) on the central CCK system of the C57BL/6J mouse. As shown by in situ hybridization, real-Time PCR and immunohistochemistry, 5 days of intracerebroventricular (i.c.v.) injections of a subeffective dose (2.3 pmol) of cortagine, a CRF(1)-selective agonist, resulted in an increase in CCK mRNA levels and CCK(2) receptor immunoreactivity in several brain regions, such as amygdala and hippocampus, known to be involved in the regulation of anxiety. Mice with elevated endogenous central CCK tone exhibited significantly higher anxiety-like behaviors in the open-field task and elevated plus maze, and enhanced conditioned fear. These behavioral changes were reversed by i.c.v. administration of the CCK(2)-selective antagonist LY225910, after 5 days of priming with cortagine. Under the same conditions, the intraperitoneal administration of the CRF(1) antagonist antalarmin was ineffective. This result indicated that once the CCK system was sensitized by prior CRF(1) activation, it exhibited its anxiogenic effects, without influence by CRF(1), possibly because of its observed downregulation. In sum, our results provide a novel model for the interaction of the CRF and CCK systems contributing to the development of hypersensitive emotional circuitry.

Indexed as

AmygdalaAnimalsAnxietyBrainCholecystokininConditioning, ClassicalCorticotropin-Releasing HormoneCRF Receptor, Type 1Dose-Response Relationship, DrugExploratory BehaviorFearHippocampusHormone AntagonistsInjections, IntraventricularMiceMice, Inbred C57BL2-(2-(5-bromo-1H-indol-3-yl)ethyl)-3-(1-methylethoxyphenyl)-4-(3H)-quinazolinoneCholecystokinincortagineCorticotropin-Releasing HormoneCRF Receptor, Type 1Hormone AntagonistsQuinazolinonesReceptor, Cholecystokinin BReceptors, Corticotropin-Releasing HormoneRecombinant Fusion ProteinsRNA, Messenger

Identifiers

PMID18195718
OpenAlexW2011995755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.